The ACSMEDI|EFMC Medicinal Chemistry Frontiers is co-organised as a collaboration between the ACS (American Chemical Society) MEDI (Division of Medicinal Chemistry) and the EFMC (European Federation for Medicinal chemistry and Chemical biology).
The Program will include:
- 3 high quality plenary lectures.
- 9 sessions on key topics in Medicinal Chemistry.
- An extensive social program to maximise your networking opportunities.
- A Poster session and an exhibition.
The ACSMEDI|EFMC Medicinal Chemistry Frontiers Meeting attracts a highly targeted audience composed of experts, researchers and early career trainees in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, and early toxicology.
Enabling Chemistries for Chemical Biology Research
Chair: Prof. Daniel Harki, University of Minnesota, US
Advances in Targeted Protein Degradation
Chair: Prof. Terry Moore, University of Illinois, US
A Focus on Early Career Investigators
Chair: Dr Melissa Grenier-Davies, GlaxoSmithKline, US
Chemical Modulation of RNA
Chair: Dr Darby Schmidt, Sonata Therapeutics, US
Computational Approaches to Identify and Target Cryptic and Allosteric Pockets
Chair: Dr Malin Lemurell, AstraZeneca, SE
Drug Targets in GPCR Signalling
Chair: Prof. György Keseru, Research Centre for Natural Sciences (RCNS), HU
Getting Out of the Starting Block: New Hit Finding and Chemotype Advancement Methods
Chair: Dr Carolyn Dzierba, BMS, US
Organic Synthesis Impacting Medicinal Chemistry & Chemical Biology
Chair: Prof. Rui Moreira, University of Lisbon, PT
Proximity-inducing Molecules and their Therapeutic Applications
Chair: Dr Amit Choudhary, Broad Institute, US
We look forward meeting you in Boston!
The Organizing Committee